GPP
PVLA

Great Point Partners’s Palvella Therapeutics PVLA Stock Holding History

Great Point Partners’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-24,568
Closed -$2.26M – 55
2022
Q3 		$2.26M Sell
24,568
-6,838
-22% -$882K 0.54% 33
2022
Q2 		$4.7M Buy
31,406
+3,918
+14% +$715K 1.13% 29
2022
Q1 		$6.66M Buy
27,488
+8,113
+42% +$2.13M 1.61% 22
2021
Q4 		$5.86M Buy
+19,375
New +$6.2M 1.3% 27

Other funds holding PVLA

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Great Point Partners's PVLA Position: Q4 2022 in Review

Great Point Partners sold out of Palvella Therapeutics (PVLA) in Q4 2022, closing a stake of 24,568 shares — an estimated $2.26M sold.

Great Point Partners first reported a position in PVLA in Q4 2021 and held it in 4 quarters. The position peaked at $6.66M in Q1 2022. 63 funds tracked by Wall St. Rank hold PVLA as of Q4 2022.

  • Great Point Partners reported no remaining Palvella Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Great Point Partners sold 24,568 Palvella Therapeutics shares in Q4 2022, an estimated $2.26M.
  • Great Point Partners first reported a position in Palvella Therapeutics in Q4 2021 and held it in 4 quarters.
  • Great Point Partners's Palvella Therapeutics position peaked at $6.66M in Q1 2022.
  • 63 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q4 2022.

Based on Great Point Partners's 13F filing for Q4 2022, filed 14 Feb 2023.